Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Edgewise Therapeutics Stock Quote

Edgewise Therapeutics (NASDAQ: EWTX)

$15.65
(3.8%)
$0.57
Price as of April 23, 2024, 4:00 p.m. ET

Edgewise Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
EWTX +117.36% -50%
S&P +21.22% +71.17% +11.35% +28%

Edgewise Therapeutics Company Info

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.